Plain-English translation of NCT07024173 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called HRS-8080 for women with advanced breast cancer that has stopped responding to hormone treatments. About 240 women will be randomly assigned to receive either this medication or one of several standard treatments that doctors typically prescribe. The goal is to find out whether the new treatment helps women live longer and feel better.
Women with advanced breast cancer often develop resistance to hormone therapy, meaning their cancer starts growing again despite treatment. This trial exists to see whether this medication offers a better option for those women.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication HRS-8080 or one of the standard treatments your doctor might normally choose for you. You would visit the study center regularly for appointments where doctors monitor how you're responding, check your health, and watch for any side effects. The study involves regular blood tests and scans to see how well the treatment is working.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
China